- To commercialize new target anti-cancer drug by developing c-myc inhibitor 

Incurix and the National Cancer Center (NCC), today announced their entry into an exclusive license agreement for the new c-myc inhibitor program that the NCC and the Korea Research Institute of Chemical Technology (KRICT) jointly developed. Under the agreement, Incurix will receive the rights to develop, manufacture and exclusively commercialize myc inhibitors in consideration of upfront, potential development/regulatory milestones and royalties on net sales of the license program of Myc inhibitor.

As the transcription factor engaged in the growth and death of cells through interactions with DNAs, the c-myc protein is involved in the occurrence and growth of cancer and is over-expressed in various cancers. Drugs that have already been developed to control c-myc expression have failed in clinical trials because of their low selectivity over target substances and the issues of side effects caused by toxicity. For this reason, there are no c-myc inhibitor drugs that have been commercialized yet. The program that Incurix has in-licensed takes a differentiated approach by having the c-myc protein directly target the DNA interacting site to increase the selectivity against the target and minimize side effects. “We will ensure the success of commercializing the FIC transcription factor-targeting drug, which many global pharmaceutical companies could not yet succeed in,” said Dr. Kyung-Chae Jeong, Incurix CEO and Senior Director at the NCC Research Center, who led the study. “If this technology succeeds in the commercialization of a drug that has so far been known as difficult in clinical applications, this will mark a significant milestone to cancer treatment,” National Cancer Center Director Lee Eun-sook said. She added, “This licensing agreement is the result of the NCC’s continuous research, and we will continue our efforts for the success in commercialization through a good research cycle of research to commercialization.” 

Incurix is a case of the NCC’s researcher-led startup and was established in 2018 by the support of bio healthcare company builder New Flight, which leads the commercialization of bio-medical fields.

http://www.biospectator.com/view/news_view.php?varAtcId=10213